Related Experiment Videos
Amyotrophic lateral sclerosis and glutamate.
A C Ludolph1, T Meyer, M W Riepe
1Department of Neurology, University of Ulm, D-89075 Ulm, Steinhövelstrasse 9, Germany. albert.ludolph@medizin.uni-ulm.de
Restorative Neurology and Neuroscience
|April 3, 2003
Summary
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. While riluzole offers some benefit, the exact cause of ALS remains unknown, and excitotoxicity may not be the sole factor.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disorder affecting the human spinal cord and brain.
- Excitotoxicity is a proposed mechanism in ALS pathogenesis, guiding research into neuroprotective therapies.
- Riluzole, an antiglutamatergic drug, is an established therapy for ALS.
Purpose of the Study:
- To review the role of excitotoxicity in amyotrophic lateral sclerosis (ALS) pathogenesis.
- To discuss the development of neuroprotective therapies for ALS.
- To highlight the limitations in understanding ALS etiology despite therapeutic advancements.
Main Methods:
- Literature review of basic research on excitotoxicity in ALS.
- Analysis of clinical data regarding riluzole therapy for ALS.
- Examination of findings from transgenic mouse models of ALS.
Main Results:
- Riluzole has been established as a therapy for ALS, demonstrating the impact of targeting antiglutamatergic pathways.
- Transgenic mouse models have facilitated in vivo studies of ALS.
- The precise etiology of ALS remains undetermined, indicating that excitotoxicity is not the exclusive pathogenic mechanism.
Conclusions:
- Despite progress, the underlying cause of amyotrophic lateral sclerosis (ALS) is not fully understood.
- While excitotoxicity plays a role, it is not the sole factor in ALS pathogenesis.
- Further research is needed to elucidate the complete etiology of ALS and develop more effective treatments.